PTGDS is a potential marker for lung adenocarcinoma identified from multi-omics pan-cancer data

Prostaglandin D2 Synthase (PTGDS) is an enzyme responsible for synthesizing prostaglandin D2. Despite its crucial role, PTGDS remains relatively understudied in tumor therapy, lacking comprehensive pan cancer analyses. Leveraging multi omics data integration, this study elucidates PTGDS's widespread dysregulation across various cancers and its correlation with patient survival. Moreover, PTGDS exhibits significant associations with stem cell scores, microenvironmental scores, microsatellite instability (MSI), tumor mutational burden (TMB), and methylation status in diverse tumor types. Additionally, immune correlations with PTGDS are evident across most cancers, with single cell transcriptome data indicating predominant associations with natural killer cells and macrophages. Notably, experimental validation reveals PTGDS's role in inhibiting lung adenocarcinoma cell A549 proliferation, linked to fatty acid degradation and cell cycle regulation. In summary, PTGDS demonstrates prognostic potential, influences pan cancer tumor immunity, and acts as a tumor suppressor in lung adenocarcinoma (LUAD).